| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 787 from our risk checks.
Selvita S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł14.68 |
| 52 Week High | zł16.46 |
| 52 Week Low | zł12.40 |
| Beta | 0.056 |
| 11 Month Change | 6.22% |
| 3 Month Change | -2.78% |
| 1 Year Change | 7.94% |
| 33 Year Change | -9.94% |
| 5 Year Change | n/a |
| Change since IPO | 18.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 787 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.1% | -4.1% | -0.008% |
| 1Y | 7.9% | -1.7% | 6.8% |
Return vs Industry: 787 exceeded the German Life Sciences industry which returned -1.7% over the past year.
Return vs Market: 787 exceeded the German Market which returned 6.8% over the past year.
Price Volatility
| 787 volatility | |
|---|---|
| 787 Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 787 has not had significant price volatility in the past 3 months.
Volatility Over Time: 787's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 387 | Boguslaw Sieczkowski | selvita.com |
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, analytical and solid state chemistry, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, inflammation, and fibrosis.
Selvita S.A. Fundamentals Summary
| 787 fundamental statistics | |
|---|---|
| Market cap | €270.38m |
| Earnings (TTM) | €15.29m |
| Revenue (TTM) | €78.98m |
17.7x
P/E Ratio3.4x
P/S RatioIs 787 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 787 income statement (TTM) | |
|---|---|
| Revenue | zł337.26m |
| Cost of Revenue | zł68.59m |
| Gross Profit | zł268.66m |
| Other Expenses | zł203.37m |
| Earnings | zł65.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | 3.56 |
| Gross Margin | 79.66% |
| Net Profit Margin | 19.36% |
| Debt/Equity Ratio | 36.1% |
How did 787 perform over the long term?
See historical performance and comparison